Preliminary evaluation of the efficacy and safety of telitacicept in children with IgA nephropathy
- 1Department of Pediatrics, Fujian Provincial Hospital Affiliated to Fuzhou University/Provincial Clinical Medical College of Fujian Medical University, Fuzhou 350001, China
Abstract
ObjectiveTo preliminarily assess the efficacy and safety of telitacicept in pediatric IgA nephropathy (IgAN).MethodsClinical data of 11 children with IgAN who received telitacicept in the Department of Pediatrics, Provincial Hospital Affiliated to Fuzhou University, from January 2024 to October 2025 were retrospectively collected. Parameters compared before and after treatment included 24-hour urinary protein, serum albumin, immunoglobulins (IgG, IgA, IgM), peripheral blood CD19+ cells, estimated glomerular filtration rate (eGFR), and glucocorticoid dosage. Adverse events were recorded.ResultsAt 4, 12, 24, 36, and 48 weeks after treatment, 24-hour urinary protein was significantly lower than baseline (all P<0.05), with the greatest reduction at 12 weeks (P<0.001). Serum albumin increased compared with baseline, reaching statistical significance at 12, 24, and 36 weeks (all P<0.05). IgG and IgA levels decreased significantly at all time points (all P<0.05), and IgM showed an overall downward trend (P<0.05). CD19+ cell counts showed no significant change (P>0.05). Glucocorticoid dosage was significantly reduced (P<0.05), while eGFR showed no significant change (P>0.05). A total of 6 adverse event episodes were recorded, predominantly mild respiratory infections; no serious adverse events occurred.ConclusionsTelitacicept can effectively reduce proteinuria in children with IgAN and demonstrates an overall favorable safety profile.
Related
- Efficacy and safety of low-dose telitacicept in IgA nephropathy: a real-world study.
- Telitacicept treatment in IgA nephropathy: A retrospective study
- Anchored Drill-Assisted Localization for Percutaneous Endoscopic Cervical Keyhole Surgery in the Treatment of Cervical Spondylotic Radiculopathy: A Technical Report and Preliminary Efficacy Evaluation
- Sensory Regulation, Theraplay®, Eye Movement Desensitisation and Reprocessing, and Dyadic Developmental Psychotherapy Integration (STEDi) for Adoptive Children who have Experienced Developmental Trauma and Attachment Disruptions: A Mixed-Methods Preliminary Evaluation
- A comparative evaluation of the efficacy and safety of clonidine and atomoxetine combined with behavioural interventions in children with autism spectrum disorder and comorbid attention-deficit/hyperactivity disorder
BibTeX
@article{jie2026preliminary,
title = {{Preliminary evaluation of the efficacy and safety of telitacicept in children with IgA nephropathy}},
author = {CHEN Jie and YU Xiao-Xia and SHI Xiao-Song and CHEN Bing and WU Shen and ZHONG Ri-Rong},
journal = {中国当代儿科杂志},
year = {2026},
month = oct,
doi = {10.7499/j.issn.1008-8830.2602053},
url = {https://doi.org/10.7499/j.issn.1008-8830.2602053},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - Preliminary evaluation of the efficacy and safety of telitacicept in children with IgA nephropathy
AU - CHEN Jie
AU - YU Xiao-Xia
AU - SHI Xiao-Song
AU - CHEN Bing
AU - WU Shen
AU - ZHONG Ri-Rong
PY - 2026
DA - 2026/10/23
JO - 中国当代儿科杂志
DO - 10.7499/j.issn.1008-8830.2602053
UR - https://doi.org/10.7499/j.issn.1008-8830.2602053
AB - ObjectiveTo preliminarily assess the efficacy and safety of telitacicept in pediatric IgA nephropathy (IgAN).MethodsClinical data of 11 children with IgAN who received telitacicept in the Department of Pediatrics, Provincial Hospital Affiliated to Fuzhou University, from January 2024 to October 2025 were retrospectively collected. Parameters compared before and after treatment included 24-hour urinary protein, serum albumin, immunoglobulins (IgG, IgA, IgM), peripheral blood CD19+ cells, estimated glomerular filtration rate (eGFR), and glucocorticoid dosage. Adverse events were recorded.ResultsAt 4, 12, 24, 36, and 48 weeks after treatment, 24-hour urinary protein was significantly lower than baseline (all P<0.05), with the greatest reduction at 12 weeks (P<0.001). Serum albumin increased compared with baseline, reaching statistical significance at 12, 24, and 36 weeks (all P<0.05). IgG and IgA levels decreased significantly at all time points (all P<0.05), and IgM showed an overall downward trend (P<0.05). CD19+ cell counts showed no significant change (P>0.05). Glucocorticoid dosage was significantly reduced (P<0.05), while eGFR showed no significant change (P>0.05). A total of 6 adverse event episodes were recorded, predominantly mild respiratory infections; no serious adverse events occurred.ConclusionsTelitacicept can effectively reduce proteinuria in children with IgAN and demonstrates an overall favorable safety profile.
SN - 1008-8830
SN - 2096-9228
ER -